#zasocitinib
LightNews LightNews
japantimes.co.jp
Takeda Pharmaceutical announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition.
Takeda’s psoriasis pill developed with AI assistance succeeds in trials
If approved, zasocitinib would stand out as one of the first drugs discovered with the help of artificial intelligence.
ebx.sh
December 18, 2025 at 7:48 PM
rheumnow.bsky.social
Novel TYK2 inhibitor Zasocitinib

Interest in TYK2, part of the JAK family, is rising due to the success of JAK inhibitors in rheumatic disease treatment. TYK2 is vital for immune activation but has limited roles in metabolic and hematopoietic pathways.

https://buff.ly/3VdI5rV
Novel TYK2 inhibitor Zasocitinib | RheumNow
Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and…
buff.ly
December 2, 2024 at 8:00 PM
blueresearch.bsky.social
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
Reported Wednesday, Sep 30 - 6:17am EDT (TheFly subscription required to read more.)
thefly.com
September 30, 2026 at 10:20 AM
blueresearch.bsky.social
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
Reported Wednesday, Sep 30 - 6:17am EDT (TheFly subscription required to read more.)
thefly.com
September 30, 2026 at 10:20 AM
canadareport.org
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Poten...

Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org

#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
September 30, 2026 at 9:01 AM
acr-journals.bsky.social
Post hoc analysis of a phase 2b trial of zasocitinib (TYK2 inhibitor) for psoriatic arthritis showed reduction of plasma biomarkers related to TYK2 signaling response, inflammation, skin & joint pathogenesis, and cartilage/bone turnover

ACR Open Rheumatology
doi.org/10.1002/acr2...
Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis. A graphical abstract
September 21, 2026 at 12:03 PM
medicalprofref.bsky.social
MPR Pod out now! This week:
✅ Approvals for spinal muscular atrophy and CKD;
🧬 Joenja gains expanded approval;
💠 FDA to speed up LSD review for depression; and
🔵 Zasocitinib granted Priority Review. #Podcast
https://www.empr.com/news/mpr-weekly-dose-podcast-287/
MPR Weekly Dose Podcast #287
Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib i...
www.empr.com
September 18, 2026 at 9:28 PM
biologist077.bsky.social
Psoriasis can be so tough. New phase 3 trial data show an oral med, zasocitinib, helped 70% of patients achieve clear or almost clear skin (a "0/1" on a doctor's scale) after 16 weeks, compared to ~11% on placebo.
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in Phase 3 Trials
Takeda announced new data from two pivotal Phase 3 studies for zasocitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The results d
www.takeda.com
March 29, 2026 at 8:04 PM
thejidjournal.bsky.social
#Pharmacological Characterization of #Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor
Mehrotra et al
doi.org/10.1016/j.ji...
#DermatologyJournal #dermatology #dermsky #dermatologists #dermresearch #dermscience #dermatologyresearch
January 4, 2026 at 1:32 PM
dermimmuno.bsky.social
Linda Stein Gold, MD, @henryfordhealth.bsky.social, describes results from the #LATITUDEAtlas study, which compared #zasocitinib with #deucravacitinib head-to-head for #psoriasis. #Dermatology #PsO

📹 Watch the full interview here:
www.docwirenews.com/post/zasocit...
Zasocitinib for Psoriasis | Docwire News
Linda Stein Gold, MD, describes results from the LATITUDE Atlas study, which compared zasocitinib with deucravacitinib head-to-head for psoriasis.
www.docwirenews.com
July 17, 2026 at 12:58 AM
cephyn.bsky.social
intuitionlabs.ai/articles/ai-...
AI Drug Discovery FDA Approvals: The 2026 Reality Check | IntuitionLabs
Analyzes whether AI has discovered any FDA-approved drugs as of 2026, covering Insilico Medicine's rentosertib Phase III trial, Takeda's zasocitinib, clinical success rates, and billions in AI drug di...
intuitionlabs.ai
September 27, 2026 at 11:00 PM
medicalprofref.bsky.social
This week's MPR Weekly Dose Pod has got you covered:
✅ Approvals for spinal muscular atrophy and CKD;
🧬 Joenja gains expanded approval;
💠 FDA to speed up LSD review for depression; and
🔵 Zasocitinib granted Priority Review. #Podcast
https://www.empr.com/news/mpr-weekly-dose-podcast-287/
MPR Weekly Dose Podcast #287
Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib i...
www.empr.com
September 20, 2026 at 6:28 PM
pharmaphorum.bsky.social
New data with #Takeda 's TYK2 inhibitor #zasocitinib suggest it is significantly more effective than #BMS 's #Sotyktu in the treatment of psoriasis.
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest
New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.
pharmaphorum.com
June 11, 2026 at 6:49 PM
ipharmaservices.bsky.social
直接比較の第3相 #乾癬 試験において、#Zasocitinib は deucravacitinib の2.5倍超のPASI 100達成率を示し、一貫した安全性と1日1回の経口投与を確認。
www.ipharmacenter.com/post/takeda-...
#ニュース #製薬 #医療 #pharma #pharmaceutical #healthcare #globalhealth #lifesciences
Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
www.ipharmacenter.com
June 12, 2026 at 10:16 AM
jlsweekly.bsky.social
Japan LS: Takeda's oral TYK2 inhibitor zasocitinib beats BMS's Sotyktu in a Ph3 psoriasis trial. SUSMED's insomnia DTx app wins insurance reimbursement.

#Bristol-MyersSquibb #Takeda #LifeSciencesJapan
https://jlsweeklyen.substack.com/p/jlsw-daily-brief-20260612-fri
June 11, 2026 at 9:18 PM
pharmaphorum.bsky.social
Armed with positive results in two phase 3 trials, #Takeda intends to file for approval of its oral #psoriasis therapy zasocitinib in the #US and other countries next year, with #BristolMyersSquibb's Sotyktu in its sights.

buff.ly/uIoOyTt
December 18, 2025 at 2:00 PM
canadareport.org
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat a...

Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org

#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
July 17, 2026 at 2:31 AM
canadareport.org
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Pso...

Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org

#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
September 14, 2026 at 9:01 AM
beyondlink.bsky.social
Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis? - BeyondLink
Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority
beyondlink.live
September 18, 2026 at 11:53 PM
kidneystories.bsky.social
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in ... - goo.gl/alerts/rQJn2S #GoogleAlerts
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
goo.gl
September 15, 2026 at 10:38 AM
pharmaphorum.bsky.social
The #FDA has started a review of the #marketingapplication for #Takeda's #TYK2inhibitor zasocitinib in #psoriasis, setting up a decision in mid-March 2027.

pharmaphorum.com/news/fda-dec...
FDA to decide on Takeda's psoriasis blockbuster hope in Q1
The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
pharmaphorum.com
September 15, 2026 at 10:24 AM
suggestionboxlive.bsky.social
📈 Top Business Stories:

1. Fda Accepts Application Takeda Zasocitinib
2. Supply Fears Oil
3. Analysis Bitcoin Late Summer Rally

Full coverage: https://suggestionbox.live/planet-business
Fda Accepts Application Takeda Zasocitinib Supply Fears Oil Analysis Bitcoin Late Summer Rally
September 14, 2026 at 11:15 PM
biostock.bsky.social
🟢 #$TAK — Regulatory Designation
FDA Grants Priority Review - Zasocitinib for Moderate-to-Severe Plaque Psoriasis
FDA granted Priority Review alongside NDA acceptance for zasocitinib in moderate-to-severe plaque psoriasis.

https://biostock.app/symbols/TAK
September 14, 2026 at 10:59 AM
rheumnow.bsky.social
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. buff.ly/z1hbis4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis | Patient Care Online
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
www.patientcareonline.com
September 14, 2026 at 9:18 PM
suggestionboxlive.bsky.social
📈 Top Business Stories:

1. Fda Accepts Application Takeda Zasocitinib
2. Supply Fears Oil
3. Analysis Bitcoin Late Summer Rally

Full coverage: https://suggestionbox.live/planet-business
Fda Accepts Application Takeda Zasocitinib Supply Fears Oil Analysis Bitcoin Late Summer Rally
September 14, 2026 at 11:15 AM